



Enhancing the T:N Ratio with the TriNav[®] Infusion System

The TriNav[®] Infusion System employs the Pressure-Enabled Drug Delivery[™] (PEDD[™]) approach to improve the T:N ratio in patients undergoing radioembolization.¹⁻³

In a retrospective study of 61 patients with primary and metastatic liver cancer (encompassing a total of 190 lesions), PEDD demonstrated significant improvements in both tumor targeting and dose delivery, compared with a traditional microcatheter (TMC):



The data supports that the use of PEDD can improve tumor targeting while reducing the risks of microspheres deposition to normal tissue, which may help protect liver function.

[Full Study Summary](#)

For more information on how PEDD can enhance radioembolization delivery, visit our website and follow us on social media.



TriNav[®] LV employs the same SmartValve technology as TriNav to enable the PEDD approach in larger vessels.

Indications For Use

The TriNav and TriNav LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.^{4,5}

Contraindications

The TriNav and TriNav LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).^{4,5}

Rx Only

For the safe and proper use of the TriNav and TriNav LV Infusion Systems, refer to their individual Instructions for Use.

References

1. d'Abadie P, Walrand S, Goffette P, et al. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. *Diagn Interv Radiol.* 2021;27(6):768-773.
2. Cook K, Gupta D, Liu Y, et al. Real-world evidence of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases. *Curr Med Res Opin.* 2024;40(4):591-598.
3. Titano JJ, Fischman AM, Cherian A, et al. End-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-TACE for solitary hepatocellular carcinoma tumors: a retrospective analysis. *Cardiovasc Intervent Radiol.* 2019;42(4):560-568.
4. TriSalus[™] TriNav[®] Infusion System Instructions for Use.
5. TriSalus[™] TriNav[®] LV Infusion System Instructions for Use.